This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Go back to News
Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII
Upstream Bio has raised another $200 million to go through Phase II studies and prepare for late-stage trials of an ex-Astellas monoclonal antibody in anticipation of competition with AstraZeneca and Amgen’s asthma drug Tezspire.
![upstream bio](https://www.accessindustries.com/wp-content/uploads/upstream-bio.png)